UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 13F
Form 13F COVER PAGE
Report for the Calendar Year or Quarter Ended: 6/30/03
-----------------------
Check Here if Amendment / /; Amendment Number:
---------
This Amendment (Check only one.): / / is a restatement.
/ / adds new holdings entries.
Institutional Investment Manager Filing this Report:
Name: Hambrecht & Quist Capital Management LLC
-----------------------------------------
Address: 30 Rowes Wharf
-----------------------------------------
Boston, MA 02110
-----------------------------------------
-----------------------------------------
Form 13F File Number: 28-04219
---------------------
The institutional investment manager filing this report and the person by
whom it is signed hereby represent that the person signing the report is
authorized to submit it, that all information contained herein is true,
correct and complete, and that it is understood that all required items,
statements, schedules, lists, and tables, are considered integral parts of
this form.
Person Signing this Report on Behalf of Reporting Manager:
Name: Kim Carroll
-------------------------------
Title: Treasurer
-------------------------------
Phone: 617-772-8525
-------------------------------
Signature, Place, and Date of Signing:
Kim Carroll Boston, MA 7/31/03
------------------------------- ----------------- -------------
[Signature] [City, State] [Date]
Report Type (Check only one.):
/X/ 13F HOLDINGS REPORT. (Check here if all holdings of this reporting
manager are reported in this report.)
/ / 13F NOTICE. (Check here if no holdings reported are in this report,
and all holdings are reported by other reporting manager(s).)
/ / 13F COMBINATION REPORT. (Check here if a portion of the holdings for
this reporting manager are reported in this report and a portion are
reported by other reporting manager(s).)
Report Type (Check only one.):
/X/ 13F HOLDINGS REPORT. (Check here if all holdings of this reporting
manager are reported in this report.)
/ / 13F NOTICE. (Check here if no holdings reported are in this report,
Form 13F SUMMARY PAGE
Report Summary:
Number of Other Included Managers: 0
------------
Form 13F Information Table Entry Total: 43
------------
Form 13F Information Table Value Total: $266,134,294
------------
(thousands)
List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all
institutional investment managers with respect to which this report is filed,
other than the manager filing this report.
[If there are no entries in this list, state "NONE" and omit the column headings
and list entries.]
No. Form 13F File Number Name
--- -------------------- -------------------
as of 6/30/03 FORM 13F
Name of Reporting Manager: HAMBRECHT & QUIST CAPITAL MANAGEMENT LLC (SEC USE ONLY)
Page 1 of 2
Item 6: Item 8:
Investment Discretion Voting Authority
--------------------- (Shares)
Item 5: (b) Item 7: ----------------
Item 1: Item 2: Item 3: Item 4: Shares of Shared- Managers
Name of Issuer Title of CUSIP Fair Market Principal (a) As (c) See (a) (b) (c)
Class Number Value Amount Sole Defined in Shared Instr. V Sole Shared None
Instr. V Other
------------------------------- -------- ------------ ------------- ----------- ----- ---------- ------ --------- ---- ------ -----
aaiPharma Common 0252W104 $4,473,000 225,000 X NA X
Adolor Common 00724X102 6,357,087 518,100 X NA X
Amgen Common 31162100 8,969,400 135,000 X NA X
Aradigm Common 038505103 630,000 350,000 X NA X
Biofield Common 090591207 131,830 878,866 X NA X
Biofield (Restricted) Common 090591207 120,000 1,000,000 X NA X
Biopure Common 09065H915 1,037,148 169,746 X NA X
Celgene Common 151020104 10,481,920 344,800 X NA X
Charles River Labs Common 159864107 4,572,778 142,100 X NA X
Corixa Common 21887F100 5,539,295 716,597 X NA X
Cubist Pharmaceuticals Common 229990981 11,038,483 1,035,505 X NA X
CV Therapeutics Common 126667104 16,203,465 546,307 X NA X
deCODE Genetics Common 24386104 4,851,600 1,555,000 X NA X
DepoMed Common 249908104 6,666,662 1,388,888 X NA X
Durect Common 266605104 631,420 262,000 X NA X
Dyax Common 26746E103 2,832,601 694,265 X NA X
Eclipsys Common 278856109 5,319,180 509,500 X NA X
Encysive Pharmaceuticals Common 29256X107 1,984,800 413,500 X NA X
Endocardial Solutions Common 292962107 10,199,996 1,666,666 X NA X
EP MedSystems Common 26881P103 2,547,750 1,075,000 X NA X
Exelixis Common 30161Q104 8,480,680 1,222,000 X NA X
Genzyme Common 372917104 5,684,800 136,000 X NA X
Gilead Sciences Common 37555B103 20,175,540 363,000 X NA X
IDEXX Laboratories Common 45168D104 8,420,000 250,000 X NA X
Impax Laboratories Common 45256B101 14,104,628 1,176,366 X NA X
IVAX Common 465823102 9,717,540 544,400 X NA X
Kosan Biosciences Common 50064W107 4,361,280 739,200 X NA X
Lexicon Genetics Common 5288872104 3,824,700 570,000 X NA X
Lynx Therapeutics Common 551812308 1,071,895 283,570 X NA X
MedImmune Common 584699102 14,948,070 411,000 X NA X
Millennium Pharmaceuticals Common 599902103 10,971,675 697,500 X NA X
Molecular Devices Common 60851C107 1,046,385 65,768 X NA X
Orthovita Common 68750U102 6,205,000 1,700,000 X NA X
Pfizer Common 717081103 9,391,250 275,000 X NA X
Pozen Common 73941U102 3,294,000 300,000 X NA X
Rigel Pharmaceuticals Common 766559108 1,236,425 114,166 X NA X
Sontra Medical (Restricted) Common 83568W109 1,554,989 1,142,702 X NA X
Telik Common 87959M109 10,713,307 666,665 X NA X
Teva Pharmaceutical Industries Common 881624209 2,590,315 45,500 X NA X
Tularik Common 899165104 2,897,431 405,405 X NA X
Vertex Pharmaceuticals Common 92532F100 2,769,620 189,700 X NA X
Vicuron Pharmaceuticals Common 925314106 9,882,624 696,941 X NA X
WebMD Common 94769M105 8,203,725 757,500 X NA X
------------
COLUMN TOTALS $266,134,294
============